Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age

    Summary
    EudraCT number
    2016-003722-16
    Trial protocol
    Outside EU/EEA   IT  
    Global end of trial date
    22 Jul 2024

    Results information
    Results version number
    v1
    This version publication date
    02 Feb 2025
    First version publication date
    02 Feb 2025
    Other versions
    v2

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    205419
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04318548
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline
    Sponsor organisation address
    Rue de l’Institut, 89,, Rixensart, Belgium, 1330
    Public contact
    GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com
    Scientific contact
    GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    03 Oct 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    21 Nov 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Jul 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    • To assess the safety and tolerability of rMenB+OMV NZ and MenACWY, when administered concomitantly or alone, in healthy subjects 16-18 years of age. • To demonstrate the non-inferiority of the antibody response to rMenB+OMV NZ given concomitantly with MenACWY to healthy subjects 16-18 years of age compared to rMenB+OMV NZ administered alone, as measured by serum bactericidal assay using human complement (hSBA) Geometric Mean Titers (GMTs) against N. meningitidis serogroup B indicator strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at 1 month after the second vaccination with rMenB+OMV NZ. • To demonstrate the non-inferiority of the antibody response to MenACWY given concomitantly with rMenB+OMV NZ to healthy subjects 16-18 years of age compared to MenACWY administered alone, as measured by hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y, at 1 month after the (study) vaccination with MenACWY.
    Protection of trial subjects
    Vaccine administration was preceded by a review of the subjects’ medical history (including previous vaccination and occurrence of undesirable events) and a general physical examination at the first visit and symptom-directed physical examination before subsequent vaccinations. Protocol procedures, including blood sampling, were done by a qualified healthcare professional. The subjects were observed closely for at least 30 minutes following the administration of the vaccine(s)/product(s), with appropriate medical treatment readily available in case of anaphylaxis and syncope.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    25 Aug 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Italy: 111
    Country: Number of subjects enrolled
    United States: 834
    Worldwide total number of subjects
    945
    EEA total number of subjects
    111
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    864
    Adults (18-64 years)
    81
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study ended on Day 271 for participants who had not reached Day 271 when Protocol Amendment 7 took effect, and on Day 451 for those who had already passed Day 271.Safety follow-up period for each participant was from Day 1 up to Day 451 or Day 271 for participants who have not reached Day 271 at the time Protocol Amendment 7 took effect.

    Pre-assignment
    Screening details
    A total of 945 participants were enrolled in the study, of which only 940 were randomized into the 3 treatment groups. After randomization, 2 participants did not receive the vaccine and making it a total of 938 participants in the exposed set.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Monitor, Data analyst, Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    MenB+MenACWY Group
    Arm description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of MenACWY vaccine, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of placebo at Day 91.
    Arm type
    Experimental

    Investigational medicinal product name
    MenACWY
    Investigational medicinal product code
    Other name
    Menveo
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of MenACWY vaccine administered intramuscularly.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of Placebo administered intramuscularly.

    Investigational medicinal product name
    rMenB+OMV NZ
    Investigational medicinal product code
    Other name
    Bexsero
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 dose of rMenB+OMV NZ vaccine administered intramuscularly.

    Arm title
    MenB Group
    Arm description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of MenACWY at Day 91.
    Arm type
    Experimental

    Investigational medicinal product name
    rMenB+OMV NZ
    Investigational medicinal product code
    Other name
    Bexsero
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 dose of rMenB+OMV NZ vaccine administered intramuscularly.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of Placebo administered intramuscularly.

    Investigational medicinal product name
    MenACWY
    Investigational medicinal product code
    Other name
    Menveo
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of MenACWY vaccine administered intramuscularly.

    Arm title
    MenACWY Group
    Arm description
    Participants received 1 dose of MenACWY vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day1, 1 dose of rMenB+OMV NZ vaccine each administered at Day 61 and at Day 91.
    Arm type
    Experimental

    Investigational medicinal product name
    rMenB+OMV NZ
    Investigational medicinal product code
    Other name
    Bexsero
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    2 dose of rMenB+OMV NZ vaccine administered intramuscularly.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of Placebo administered intramuscularly.

    Investigational medicinal product name
    MenACWY
    Investigational medicinal product code
    Other name
    Menveo
    Pharmaceutical forms
    Powder and solution for solution for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 dose of MenACWY vaccine administered intramuscularly.

    Number of subjects in period 1 [1]
    MenB+MenACWY Group MenB Group MenACWY Group
    Started
    310
    308
    320
    Completed
    297
    284
    298
    Not completed
    13
    24
    22
         Adverse event, non-fatal
    -
    -
    1
         Migrated / moved from the study area
    -
    -
    1
         Not specified
    1
    2
    3
         Lost to follow-up
    6
    13
    9
         Consent withdrawal, not due to a (S)AE
    5
    9
    6
         Protocol deviation
    1
    -
    2
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: A total of 945 participants were enrolled in the study, of which only 940 were randomized into the 3 treatment groups. After randomization, 2 participants did not receive the vaccine and making it a total of 938 participants in the exposed set.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    MenB+MenACWY Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of MenACWY vaccine, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of placebo at Day 91.

    Reporting group title
    MenB Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of MenACWY at Day 91.

    Reporting group title
    MenACWY Group
    Reporting group description
    Participants received 1 dose of MenACWY vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day1, 1 dose of rMenB+OMV NZ vaccine each administered at Day 61 and at Day 91.

    Reporting group values
    MenB+MenACWY Group MenB Group MenACWY Group Total
    Number of subjects
    310 308 320 938
    Age categorical
    Units: Subjects
        In utero
    0 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0 0
        Newborns (0-27 days)
    0 0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0 0
        Children (2-11 years)
    0 0 0 0
        Adolescents (12-17 years)
    286 283 288 857
        Adults (18-64 years)
    24 25 32 81
        From 65-84 years
    0 0 0 0
        85 years and over
    0 0 0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    16.4 ( 0.7 ) 16.4 ( 0.7 ) 16.5 ( 0.7 ) -
    Sex: Female, Male
    Units: Participants
        Male
    154 170 157 481
        Female
    156 138 163 457
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    46 38 37 121
        Not Hispanic or Latino
    263 270 282 815
        Unknown or Not Reported
    1 0 1 2

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    MenB+MenACWY Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of MenACWY vaccine, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of placebo at Day 91.

    Reporting group title
    MenB Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of MenACWY at Day 91.

    Reporting group title
    MenACWY Group
    Reporting group description
    Participants received 1 dose of MenACWY vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day1, 1 dose of rMenB+OMV NZ vaccine each administered at Day 61 and at Day 91.

    Primary: Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 1

    Close Top of page
    End point title
    Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 1 [1]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs = occurrence of the symptom regardless of intensity grade. Analysis was performed on the Exposed set (ES), which included all participants who received at least one dose of the study treatment and had the electronic diary (eDiary) for solicited events completed after the administration of study treatment and for whom data were available during the specified period. Allocation per group is based on the treatment administered. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the rMenB+OMV NZ vaccination at Day 1
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    306
    0 [2]
    Units: Participants
        Erythema
    12
    12
        Induration
    14
    22
        Pain
    246
    247
        Swelling
    15
    18
    Notes
    [2] - Participants in this group did not receive rMenB+OMV NZ on Day 1 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 61

    Close Top of page
    End point title
    Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 61 [3]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs = occurrence of the symptom regardless of intensity grade. Analysis was performed on the Exposed set (ES), which included all participants who received at least one dose of the study treatment and had the electronic diary (eDiary) for solicited events completed after the administration of study treatment and for whom data were available during the specified period. Allocation per group is based on the treatment administered. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the rMenB+OMV NZ vaccination at Day 61
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    306
    287
    Units: Participants
        Erythema
    17
    17
    8
        Induration
    18
    19
    6
        Pain
    240
    228
    238
        Swelling
    16
    16
    7
    No statistical analyses for this end point

    Primary: Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 91

    Close Top of page
    End point title
    Number of participants with solicited local adverse events (AEs) after the vaccination with rMenB+OMV NZ at Day 91 [4]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs = occurrence of the symptom regardless of intensity grade. Analysis was performed on the Exposed set (ES), which included all participants who received at least one dose of the study treatment and had the electronic diary (eDiary) for solicited events completed after the administration of study treatment and for whom data were available during the specified period. Allocation per group is based on the treatment administered. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the rMenB+OMV NZ vaccination at Day 91
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    0 [5]
    0 [6]
    287
    Units: Participants
        Erythema
    14
        Induration
    11
        Pain
    205
        Swelling
    13
    Notes
    [5] - Participants in this group did not receive rMenB+OMV NZ on Day 91 hence zero participants.
    [6] - Participants in this group did not receive rMenB+OMV NZ on Day 91 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local AEs after the vaccination with MenACWY at Day 1

    Close Top of page
    End point title
    Number of participants with solicited local AEs after the vaccination with MenACWY at Day 1 [7]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs= occurrence of the symptom regardless of intensity grade. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the MenACWY vaccination at Day 1
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    0 [8]
    319
    Units: Participants
        Erythema
    5
    6
        Induration
    7
    7
        Pain
    93
    104
        Swelling
    5
    5
    Notes
    [8] - Participants in this group did not receive MenACWY on Day 1 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local AEs after the vaccination with MenACWY at Day 61

    Close Top of page
    End point title
    Number of participants with solicited local AEs after the vaccination with MenACWY at Day 61 [9]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs= occurrence of the symptom regardless of intensity grade. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis. 1 participant in MenB Group received wrong study treatment at Day 61 (MenACWY vaccine instead of rMenB+OMV NZ), hence was considered in the analysis population.
    End point type
    Primary
    End point timeframe
    During 7 days after the MenACWY vaccination at Day 61
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    0 [10]
    1
    0 [11]
    Units: Participants
        Erythema
    0
        Induration
    0
        Pain
    1
        Swelling
    0
    Notes
    [10] - Participants in this group did not receive MenACWY on Day 61 hence zero participants.
    [11] - Participants in this group did not receive MenACWY on Day 61 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local AEs after the vaccination with MenACWY at Day 91

    Close Top of page
    End point title
    Number of participants with solicited local AEs after the vaccination with MenACWY at Day 91 [12]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs= occurrence of the symptom regardless of intensity grade. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the MenACWY vaccination at Day 91
    Notes
    [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    0 [13]
    265
    0 [14]
    Units: Participants
        Erythema
    4
        Induration
    1
        Pain
    38
        Swelling
    5
    Notes
    [13] - Participants in this group did not receive MenACWY on Day 91 hence zero participants.
    [14] - Participants in this group did not receive MenACWY on Day 91 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local AEs after the vaccination with Placebo at Day 1

    Close Top of page
    End point title
    Number of participants with solicited local AEs after the vaccination with Placebo at Day 1 [15]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs = occurrence of the symptom regardless of intensity grade. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the Placebo vaccination at Day 1
    Notes
    [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    0 [16]
    306
    320
    Units: Participants
        Erythema
    2
    2
        Induration
    5
    0
        Pain
    78
    77
        Swelling
    2
    1
    Notes
    [16] - Participants in this group did not receive Placebo on Day 1 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited local AEs after the vaccination with Placebo at Day 91

    Close Top of page
    End point title
    Number of participants with solicited local AEs after the vaccination with Placebo at Day 91 [17]
    End point description
    Solicited local adverse events assessed are injection site pain, erythema, swelling, induration. Any solicited local AEs = occurrence of the symptom regardless of intensity grade. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis. 1 participant in MenACWY Group received wrong study treatment at Day 91 (placebo instead of rMenB+OMV NZ), hence was considered in the analysis population.
    End point type
    Primary
    End point timeframe
    During 7 days after the Placebo vaccination at Day 91
    Notes
    [17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    282
    0 [18]
    320
    Units: Participants
        Erythema
    1
    0
        Induration
    1
    0
        Pain
    25
    0
        Swelling
    0
    0
    Notes
    [18] - Participants in this group did not receive Placebo on Day 91 hence zero participants.
    No statistical analyses for this end point

    Primary: Number of participants with solicited systemic AEs at Day 1

    Close Top of page
    End point title
    Number of participants with solicited systemic AEs at Day 1 [19]
    End point description
    Solicited systemic adverse events assessed are fever [temperature >= 38.0°C], nausea, fatigue, myalgia, arthralgia, and headache. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the first study intervention administration occurring at Day 1
    Notes
    [19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    306
    320
    Units: Participants
        Arthralgia
    24
    32
    24
        Fatigue
    114
    118
    108
        Headache
    128
    135
    134
        Myalgia
    36
    49
    31
        Nausea
    46
    57
    51
        Fever
    7
    10
    2
    No statistical analyses for this end point

    Primary: Number of participants with solicited systemic AEs at Day 61

    Close Top of page
    End point title
    Number of participants with solicited systemic AEs at Day 61 [20]
    End point description
    Solicited systemic adverse events assessed are fever [temperature >= 38.0°C], nausea, fatigue, myalgia, arthralgia, and headache. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the second study intervention administration occurring at Day 61
    Notes
    [20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    306
    320
    Units: Participants
        Arthralgia
    28
    24
    27
        Fatigue
    96
    101
    88
        Headache
    112
    103
    93
        Myalgia
    41
    42
    43
        Nausea
    37
    37
    40
        Fever
    4
    8
    6
    No statistical analyses for this end point

    Primary: Number of participants with solicited systemic AEs at Day 91

    Close Top of page
    End point title
    Number of participants with solicited systemic AEs at Day 91 [21]
    End point description
    Solicited systemic adverse events assessed are fever [temperature >= 38.0°C], nausea, fatigue, myalgia, arthralgia, and headache. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 7 days after the third study intervention administration occurring at Day 91
    Notes
    [21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    307
    306
    320
    Units: Participants
        Arthralgia
    7
    8
    24
        Fatigue
    38
    59
    86
        Headache
    56
    53
    84
        Myalgia
    7
    16
    39
        Nausea
    20
    18
    31
        Fever
    2
    2
    6
    No statistical analyses for this end point

    Primary: Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 1

    Close Top of page
    End point title
    Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 1 [22]
    End point description
    Unsolicited adverse events are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms are reported as an unsolicited adverse event. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits or safety follow-up calls is entered into the subject's electronic Case Report Form (eCRF) as an unsolicited AE. Serious Adverse Events (SAEs) are any untoward medical occurrence that result in death, are life-threatening, require hospitalization or prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the first study intervention administration occurring at Day 1
    Notes
    [22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    49
    54
    55
    No statistical analyses for this end point

    Primary: Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 61

    Close Top of page
    End point title
    Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 61 [23]
    End point description
    Unsolicited adverse events are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms are reported as an unsolicited adverse event. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits or safety follow-up calls is entered into the subject's electronic Case Report Form (eCRF) as an unsolicited AE. Serious Adverse Events (SAEs) are any untoward medical occurrence that result in death, are life-threatening, require hospitalization or prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the second study intervention administration occurring at Day 61
    Notes
    [23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    51
    47
    44
    No statistical analyses for this end point

    Primary: Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 91

    Close Top of page
    End point title
    Number of participants with any unsolicited AEs (including all Serious Adverse Events) at Day 91 [24]
    End point description
    Unsolicited adverse events are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms are reported as an unsolicited adverse event. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits or safety follow-up calls is entered into the subject's electronic Case Report Form (eCRF) as an unsolicited AE. Serious Adverse Events (SAEs) are any untoward medical occurrence that result in death, are life-threatening, require hospitalization or prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the third study intervention administration occurring at Day 91
    Notes
    [24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    37
    37
    38
    No statistical analyses for this end point

    Primary: Number of participants with any AEs/SAEs leading to withdrawal at Day 1

    Close Top of page
    End point title
    Number of participants with any AEs/SAEs leading to withdrawal at Day 1 [25]
    End point description
    Unsolicited AEs are any AE reported beyond those solicited during the clinical study. A solicited symptom reported outside the designated follow-up period is considered an unsolicited AE. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits/safety follow-up calls is entered into the subject's eCRF as an unsolicited AE. SAEs are any untoward medical occurrence that result in death, are life-threatening, require hospitalization/prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. A participant was considered a ‘withdrawal’ from study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Analysis was performed on ES population,participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the first study intervention administration occurring at Day 1
    Notes
    [25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    0
    0
    1
    No statistical analyses for this end point

    Primary: Number of participants with any AEs/SAEs leading to withdrawal at Day 61

    Close Top of page
    End point title
    Number of participants with any AEs/SAEs leading to withdrawal at Day 61 [26]
    End point description
    Unsolicited AEs are any AE reported beyond those solicited during the clinical study. A solicited symptom reported outside the designated follow-up period is considered an unsolicited AE. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits/safety follow-up calls is entered into the subject's eCRF as an unsolicited AE. SAEs are any untoward medical occurrence that result in death, are life-threatening, require hospitalization/prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. A participant was considered a ‘withdrawal’ from study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Analysis was performed on ES population,participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the second study intervention administration occurring at Day 61
    Notes
    [26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    0
    0
    0
    No statistical analyses for this end point

    Primary: Number of participants with any medically attended AEs at Day 1

    Close Top of page
    End point title
    Number of participants with any medically attended AEs at Day 1 [27]
    End point description
    Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the first study intervention administration occurring at Day 1
    Notes
    [27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    28
    36
    26
    No statistical analyses for this end point

    Primary: Number of participants with any AEs/SAEs leading to withdrawal at Day 91

    Close Top of page
    End point title
    Number of participants with any AEs/SAEs leading to withdrawal at Day 91 [28]
    End point description
    Unsolicited AEs are any AE reported beyond those solicited during the clinical study. A solicited symptom reported outside the designated follow-up period is considered an unsolicited AE. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits/safety follow-up calls is entered into the subject's eCRF as an unsolicited AE. SAEs are any untoward medical occurrence that result in death, are life-threatening, require hospitalization/prolongation of existing hospitalization, result in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. A participant was considered a ‘withdrawal’ from study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this participant from the date of withdrawal/last contact. Analysis was performed on ES population,participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the third study intervention administration occurring at Day 91
    Notes
    [28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    0
    0
    0
    No statistical analyses for this end point

    Primary: Number of participants with any medically attended AEs at Day 61

    Close Top of page
    End point title
    Number of participants with any medically attended AEs at Day 61 [29]
    End point description
    Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the second study intervention administration occurring at Day 61
    Notes
    [29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    28
    32
    25
    No statistical analyses for this end point

    Primary: Number of participants with any medically attended AEs at Day 91

    Close Top of page
    End point title
    Number of participants with any medically attended AEs at Day 91 [30]
    End point description
    Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    During 30 days after the third study intervention administration occurring at Day 91
    Notes
    [30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    19
    21
    17
    No statistical analyses for this end point

    Primary: Number of participants with any SAEs, AEs leading to withdrawal and medically attended AEs

    Close Top of page
    End point title
    Number of participants with any SAEs, AEs leading to withdrawal and medically attended AEs [31]
    End point description
    SAEs, AEs leading to withdrawal and medically attended AEs were assessed throughout the study period and are reported in this outcome measure. Analysis was performed on the ES population, which included all participants who received at least one dose of the study treatment. Allocation per group is based on the treatment administered.
    End point type
    Primary
    End point timeframe
    Throughout the study period (Day 1 to Day 271)
    Notes
    [31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
        SAEs
    2
    3
    5
        AEs leading to withdrawal
    0
    0
    1
        Medically attended AEs
    93
    103
    96
    No statistical analyses for this end point

    Primary: Number of participants who received rMenB+OMV NZ with adverse events of special interest (AESI)

    Close Top of page
    End point title
    Number of participants who received rMenB+OMV NZ with adverse events of special interest (AESI) [32]
    End point description
    AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. Analysis was performed on ES population. Only participants with data available at specified timepoints were included in the analysis.
    End point type
    Primary
    End point timeframe
    Throughout the study period (Day 1 to Day 271)
    Notes
    [32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: Participants
    0
    0
    0
    No statistical analyses for this end point

    Primary: Number of participants with any SAEs and AEs leading to withdrawal

    Close Top of page
    End point title
    Number of participants with any SAEs and AEs leading to withdrawal [33]
    End point description
    Unsolicited AEs are any AE reported beyond those solicited during the clinical study. A solicited symptom reported outside the designated follow-up period is considered an unsolicited AE. Any solicited AE that has not resolved within 30 days post vaccination and is reported during clinic visits/safety follow-up calls is entered into the subject's eCRF as an unsolicited AE. SAEs are any untoward medical occurrence that result in death, are life-threatening, require hospitalization or prolongation, causing disability/incapacity and is a congenital anomaly/birth defect in the offspring of study subject. A participant is considered a 'withdrawal' from the study if no further study procedures, follow-ups, or data collection have occurred since the withdrawal/last contact date. Analysis was performed on ES population,participants with data available at specified timepoints (during safety follow-up period from Day 271 to Day 451) were included in the analysis.
    End point type
    Primary
    End point timeframe
    During safety follow-up (Day 271 to Day 451)
    Notes
    [33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    88
    90
    87
    Units: Participants
        SAEs
    0
    1
    2
        AEs leading to withdrawal
    0
    0
    0
    No statistical analyses for this end point

    Primary: Number of participants who received rMenB+OMV NZ with AESI

    Close Top of page
    End point title
    Number of participants who received rMenB+OMV NZ with AESI [34]
    End point description
    AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. Analysis was performed on ES population. Only participants with data available at specified timepoints (during safety follow-up period from Day 271 to Day 451) were included in the analysis.
    End point type
    Primary
    End point timeframe
    During safety follow-up (Day 271 to Day 451)
    Notes
    [34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    88
    90
    87
    Units: Participants
    0
    0
    0
    No statistical analyses for this end point

    Primary: Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) against each of the N. meningitidis serogroup B strains at 1 month after the second vaccination with rMenB+OMV NZ (groups MenB+MenACWY and MenB), and between-group GMT ratios

    Close Top of page
    End point title
    Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) against each of the N. meningitidis serogroup B strains at 1 month after the second vaccination with rMenB+OMV NZ (groups MenB+MenACWY and MenB), and between-group GMT ratios [35]
    End point description
    hSBA titers were measured by serum bactericidal assay and expressed as Geometric Mean Titers (GMTs) against N. meningitidis serogroup B indicator strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]). Analysis was performed on the Per Protocol Set (PPS), which included participants who received at least 1 dose of the study intervention to which they were randomized and had post-vaccination data available at the specified timepoint minus participants with protocol deviations that led to exclusion from the PPS.
    End point type
    Primary
    End point timeframe
    At Day 91 (1 month after the second vaccination with rMenB+OMV NZ in MenB+MenACWY and MenB groups)
    Notes
    [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the second vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    274
    267
    Units: Titers
    geometric mean (confidence interval 95%)
        fHbp (M14459)
    16.9 (14.4 to 19.8)
    18.7 (15.9 to 21.9)
        NadA (96217)
    239.6 (202.9 to 283.0)
    272.4 (231.1 to 321.0)
        PorA (NZ98/254)
    18.8 (15.6 to 22.6)
    21.3 (17.7 to 25.6)
        NHBA (M13520)
    19.0 (15.6 to 23.1)
    20.5 (16.9 to 24.9)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    To demonstrate the non-inferiority (NI) of the antibody response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis serogroup B indicator strains at one month after the second vaccination with rMenB+OMV NZ (at Day 91).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    541
    Analysis specification
    Pre-specified
    Analysis type
    [36]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.9
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.77
         upper limit
    1.06
    Notes
    [36] - NI was to be demonstrated if the lower limit (LL) of the 2-sided 95% CI of the GMT ratio between the MenB+MenACWY group and MenB group for hSBA titers against M14459 (fHbp) strain was above (>) 0.5
    Statistical analysis title
    Statistical Analysis 2
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis serogroup B indicator strains at one month after the second vaccination with rMenB+OMV NZ (at Day 91).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    541
    Analysis specification
    Pre-specified
    Analysis type
    [37]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.75
         upper limit
    1.04
    Notes
    [37] - NI was to be demonstrated if LL of the 2-sided 95% CI of the GMT ratio between the MenB+MenACWY group and MenB group for hSBA titers against 96217 (NadA) strain was >0.5
    Statistical analysis title
    Statistical Analysis 3
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis serogroup B indicator strains at one month after the second vaccination with rMenB+OMV NZ (at Day 91).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    541
    Analysis specification
    Pre-specified
    Analysis type
    [38]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.93
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.76
         upper limit
    1.12
    Notes
    [38] - NI was to be demonstrated if LL of the 2-sided 95% CI of the GMT ratio between the MenB+MenACWY group and MenB group for hSBA titers against NZ98/254 (PorA) strain was >0.5.
    Statistical analysis title
    Statistical Analysis 4
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis serogroup B indicator strains at one month after the second vaccination with rMenB+OMV NZ (at Day 91).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    541
    Analysis specification
    Pre-specified
    Analysis type
    [39]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.73
         upper limit
    1.06
    Notes
    [39] - NI was to be demonstrated if LL of the 2-sided 95% CI of the GMT ratio between the MenB+MenACWY group and MenB group for hSBA titers against M13520 (NHBA) strain was >0.5

    Primary: hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y after vaccination with MenACWY (groups MenB+MenACWY and MenACWY), and between-group GMT ratios

    Close Top of page
    End point title
    hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y after vaccination with MenACWY (groups MenB+MenACWY and MenACWY), and between-group GMT ratios [40]
    End point description
    hSBA titers were measured by serum bactericidal assay and expressed as GMTs against each of the 4 serogroups Men A, Men C, Men W and Men Y. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Primary
    End point timeframe
    At Day 31 (1 month after the vaccination with MenACWY in MenACWY and MenB+MenACWY groups)
    Notes
    [40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the immune response to MenACWY in healthy subjects 16-18 years of age against each of the serogroups A, C, W and Y, at one month after the (study) vaccination with MenACWY.
    End point values
    MenB+MenACWY Group MenACWY Group
    Number of subjects analysed
    295
    303
    Units: Titers
    geometric mean (confidence interval 95%)
        Men A
    2388.8 (1977.2 to 2886.1)
    2536.1 (2095.7 to 3069.1)
        Men C
    2075.9 (1602.5 to 2689.3)
    1867.6 (1438.7 to 2424.2)
        Men W
    2299.3 (1902.5 to 2778.9)
    2305.7 (1905.3 to 2790.4)
        Men Y
    2897.3 (2359.2 to 3558.3)
    2802.0 (2278.3 to 3446.2)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to MenACWY given concomitantly with rMenB+OMV NZ compared to MenACWY administered alone, as measured by hSBA GMTs against the N. meningitidis serogroup Men A, at one month after the vaccination with MenACWY (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenACWY Group
    Number of subjects included in analysis
    598
    Analysis specification
    Pre-specified
    Analysis type
    [41]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.94
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.78
         upper limit
    1.14
    Notes
    [41] - NI was to be demonstrated if LL of the 2-sided 95% CI of the between-group ratio of hSBA GMTs between MenB+MenACWY group and MenACWY group for Men A serogroup was >0.5.
    Statistical analysis title
    Statistical Analysis 4
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to MenACWY given concomitantly with rMenB+OMV NZ compared to MenACWY administered alone, as measured by hSBA GMTs against the N. meningitidis serogroup Men Y, at one month after the vaccination with MenACWY (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenACWY Group
    Number of subjects included in analysis
    598
    Analysis specification
    Pre-specified
    Analysis type
    [42]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    1.03
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.84
         upper limit
    1.27
    Notes
    [42] - NI was to be demonstrated if LL of the 2-sided 95% CI of the between-group ratio of hSBA GMTs between MenB+MenACWY group and MenACWY group for Men Y serogroup was >0.5.
    Statistical analysis title
    Statistical Analysis 3
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to MenACWY given concomitantly with rMenB+OMV NZ compared to MenACWY administered alone, as measured by hSBA GMTs against the N. meningitidis serogroup Men W, at one month after the vaccination with MenACWY (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenACWY Group
    Number of subjects included in analysis
    598
    Analysis specification
    Pre-specified
    Analysis type
    [43]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.82
         upper limit
    1.21
    Notes
    [43] - NI was to be demonstrated if LL of the 2-sided 95% CI of the between-group ratio of hSBA GMTs between MenB+MenACWY group and MenACWY group for Men W serogroup was >0.5.
    Statistical analysis title
    Statistical Analysis 2
    Statistical analysis description
    To demonstrate the non-inferiority of the antibody response to MenACWY given concomitantly with rMenB+OMV NZ compared to MenACWY administered alone, as measured by hSBA GMTs against the N. meningitidis serogroup Men C, at one month after the vaccination with MenACWY (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenACWY Group
    Number of subjects included in analysis
    598
    Analysis specification
    Pre-specified
    Analysis type
    [44]
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    1.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.86
         upper limit
    1.44
    Notes
    [44] - NI was to be demonstrated if LL of the 2-sided 95% CI of the between-group ratio of hSBA GMTs between MenB+MenACWY group and MenACWY group for Men C serogroup was >0.5.

    Secondary: hSBA Geometric Mean Concentrations (GMCs) measured by ECL against each of the N. meningitidis serogroups after MenACWY vaccination

    Close Top of page
    End point title
    hSBA Geometric Mean Concentrations (GMCs) measured by ECL against each of the N. meningitidis serogroups after MenACWY vaccination
    End point description
    Immune response to MenACWY given with or without rMenB+OMV NZ, as measured by lectrochemiluminescence-based multiplex (ECL) GMCs against each of the serogroups A, C, W and Y. ECL (validated assay) was used because ELISA is not validated. Analysis was performed on the PPS population, which included participants who received at least 1 dose of the study intervention to which they were randomized and had post-vaccination data available at the specified timepoint minus participants with protocol deviations that led to exclusion from the PPS. 99999" is used as a placeholder value for the results for all the groups since the analysis of final results for these groups is ongoing and will be updated subsequently.
    End point type
    Secondary
    End point timeframe
    At Day 31 (1 month after the vaccination of MenACWY in MenACWY and MenB+MenACWY groups)
    End point values
    MenB+MenACWY Group MenB Group MenACWY Group
    Number of subjects analysed
    310
    308
    320
    Units: IU/L
        geometric mean (confidence interval 95%)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    No statistical analyses for this end point

    Secondary: hSBA GMTs against each of the serogroup B strains in both MenB+MenACWY and MenB Groups after first rMenB+OMV NZ vaccination and between-group GMT ratios

    Close Top of page
    End point title
    hSBA GMTs against each of the serogroup B strains in both MenB+MenACWY and MenB Groups after first rMenB+OMV NZ vaccination and between-group GMT ratios [45]
    End point description
    hSBA titers were measured by bactericidal activity against N. meningitidis serogroup B indicator strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]) and expressed in GMTs. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At Day 31 (1 month after first vaccination with rMenB+OMV NZ)
    Notes
    [45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the first vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    294
    294
    Units: Titers
    geometric mean (confidence interval 95%)
        fHbp (M14459)
    4.3 (3.6 to 5.1)
    5.6 (4.7 to 6.7)
        NadA (96217)
    45.2 (36.0 to 56.9)
    73.4 (58.5 to 91.9)
        PorA (NZ98/254)
    4.2 (3.5 to 5.0)
    5.6 (4.7 to 6.6)
        NHBA (M13520)
    6.4 (5.1 to 8.1)
    8.8 (7.0 to 11.1)
    Statistical analysis title
    Statistical Analysis 1
    Statistical analysis description
    To assess the immune response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis M14459 (fHbp) strain at one month after the fisrt vaccination with rMenB+OMV NZ (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    588
    Analysis specification
    Pre-specified
    Analysis type
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.76
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.64
         upper limit
    0.91
    Statistical analysis title
    Statistical Analysis 4
    Statistical analysis description
    To assess the immune response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis M13520 (NHBA) at one month after the second vaccination with rMenB+OMV NZ (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    588
    Analysis specification
    Pre-specified
    Analysis type
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.76
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.64
         upper limit
    0.9
    Statistical analysis title
    Statistical Analysis 3
    Statistical analysis description
    To assess the immune response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis NZ98/254 (PorA) strain at one month after the second vaccination with rMenB+OMV NZ (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    588
    Analysis specification
    Pre-specified
    Analysis type
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.73
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.58
         upper limit
    0.91
    Statistical analysis title
    Statistical Analysis 2
    Statistical analysis description
    To assess the immune response to rMenB+OMV NZ given concomitantly with MenACWY compared to rMenB+OMV NZ administered alone, measured by hSBA GMTs against N. meningitidis 96217 (NadA) strain at one month after the second vaccination with rMenB+OMV NZ (at Day 31).
    Comparison groups
    MenB+MenACWY Group v MenB Group
    Number of subjects included in analysis
    588
    Analysis specification
    Pre-specified
    Analysis type
    Method
    ANOVA
    Parameter type
    GMT Ratio
    Point estimate
    0.62
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.49
         upper limit
    0.77

    Secondary: Geometric mean ratios (GMRs) against each of the N. meningitidis serogroup B strains in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    Geometric mean ratios (GMRs) against each of the N. meningitidis serogroup B strains in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination [46]
    End point description
    The immune response to rMenB+OMV NZ was measured by bactericidal activity against N. meningitidis serogroup B indicator strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]) in terms of GMRs (after vaccination/baseline). Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At Day 31 (1 month after first rMenB+OMV NZ vaccination) compared to the baseline (Day 1)
    Notes
    [46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the immune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the first vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    294
    294
    Units: Ratio
    geometric mean (confidence interval 95%)
        fHbp (M14459)
    1.6 (1.4 to 1.9)
    2.0 (1.7 to 2.4)
        NadA (96217)
    5.9 (4.7 to 7.4)
    9.3 (7.5 to 11.6)
        PorA (NZ98/254)
    1.4 (1.2 to 1.6)
    1.8 (1.5 to 2.1)
        NHBA (M13520)
    1.8 (1.5 to 2.2)
    2.3 (1.9 to 2.8)
    No statistical analyses for this end point

    Secondary: GMRs against each of the N. meningitidis serogroup B strains in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    GMRs against each of the N. meningitidis serogroup B strains in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination [47]
    End point description
    The immune response to rMenB+OMV NZ was measured by bactericidal activity against N. meningitidis serogroup B indicator strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]) in terms of GMRs (after vaccination/baseline). Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At Day 91 (1 month after the second rMenB+OMV NZ vaccination) compared to the baseline (Day 1)
    Notes
    [47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the second vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    274
    267
    Units: Ratio
    geometric mean (confidence interval 95%)
        fHbp (M14459)
    6.4 (5.5 to 7.5)
    7.0 (5.9 to 8.1)
        NadA (96217)
    30.7 (25.8 to 36.6)
    35.1 (29.5 to 41.7)
        PorA (NZ98/254)
    6.0 (5.0 to 7.2)
    6.9 (5.8 to 8.3)
        NHBA (M13520)
    5.2 (4.4 to 6.2)
    5.6 (4.7 to 6.6)
    No statistical analyses for this end point

    Secondary: Percentage of participants with hSBA titers >= lower limit of quantitation (LLOQ) for each and all serogroup B test strains in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    Percentage of participants with hSBA titers >= lower limit of quantitation (LLOQ) for each and all serogroup B test strains in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination [48]
    End point description
    The immune response to rMenB+OMV NZ vaccine is evaluated by measuring bactericidal activity in terms of participants with hSBA titers >= LLOQ against N. meningitidis serogroup B test strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]). Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At Day 31 (one month after the first rMenB+OMV NZ vaccination)
    Notes
    [48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the first vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    294
    294
    Units: Percentage of participants
    number (confidence interval 95%)
        fHbp (M14459)
    32.3 (27.0 to 38.0)
    44.9 (39.1 to 50.8)
        NadA (96217)
    77.9 (72.7 to 82.5)
    85.7 (81.2 to 89.5)
        PorA ( NZ98/254)
    21.1 (16.6 to 26.2)
    30.4 (25.2 to 36.0)
        NHBA (M13520)
    37.1 (31.5 to 42.9)
    44.4 (38.6 to 50.3)
    No statistical analyses for this end point

    Secondary: Percentage of participants with hSBA titers >= LLOQ for each and all of the serogroup B test strains in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    Percentage of participants with hSBA titers >= LLOQ for each and all of the serogroup B test strains in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination [49]
    End point description
    The immune response to rMenB+OMV NZ vaccine is evaluated by measuring bactericidal activity in terms of participants with hSBA titers >= LLOQ against N. meningitidis serogroup B test strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]). Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At Day 91 (1 month after the second rMenB+OMV NZ vaccination)
    Notes
    [49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the second vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    274
    267
    Units: Percentage of participants
    number (confidence interval 95%)
        fHbp (M14459 )
    92.3 (88.5 to 95.2)
    92.5 (88.6 to 95.3)
        NadA (96217)
    99.6 (98.0 to 100)
    99.6 (97.9 to 100)
        PorA (NZ98/254)
    83.2 (78.2 to 87.4)
    85.0 (80.1 to 89.0)
        NHBA (M13520)
    84.2 (79.4 to 88.4)
    90.2 (86.0 to 93.5)
    No statistical analyses for this end point

    Secondary: Percentage of participants with 4-fold increase in hSBA titers relative to baseline in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    Percentage of participants with 4-fold increase in hSBA titers relative to baseline in both MenB+MenACWY and MenB Groups after the first rMenB+OMV NZ vaccination [50]
    End point description
    The immune response to rMenB+OMV NZ vaccine is evaluated by measuring bactericidal activity against each of N. meningitidis serogroup B test strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]) in terms of the Four-fold increase defined as: - For a pre-vaccination titer < limit of detection (LOD), a post-vaccination titer of >= 4-fold the LOD or >= LLOQ, whichever is greater, - For a pre-vaccination titer >= LOD but <LLOQ, a post vaccination titer of at least 4-fold the LLOQ, - For a pre-vaccination titer >= LLOQ, a post vaccination titer of at least 4-fold the pre-vaccination titer. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At 1 month after the first rMenB+OMV NZ vaccination (i.e at Day 31) relative to baseline (i.e. Day 1)
    Notes
    [50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the first vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    293
    293
    Units: Percentage of participants
    number (confidence interval 95%)
        fHbp (M14459)
    14.7 (10.8 to 19.3)
    21.0 (16.4 to 26.1)
        NadA (96217)
    68.9 (63.3 to 74.2)
    78.4 (73.3 to 83.0)
        PorA (NZ98/254)
    8.9 (5.9 to 12.7)
    16.4 (12.4 to 21.2)
        NHBA (M13520)
    17.4 (13.2 to 22.2)
    25.3 (20.4 to 30.6)
    No statistical analyses for this end point

    Secondary: Percentage of participants with hSBA titers >=LLOQ for each of the serogroup A, C, W and Y in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination

    Close Top of page
    End point title
    Percentage of participants with hSBA titers >=LLOQ for each of the serogroup A, C, W and Y in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination [51]
    End point description
    The immune response to MenACWY vaccines is expressed in terms of percentage of participants with hSBA titers >=LLOQ for each of the serogroup Men A, Men C, Men W and Men Y. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At baseline (Day 1) and at one month after the MenACWY vaccination (i.e. Day 31)
    Notes
    [51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assesses the immune response to MenACWY in healthy subjects 16-18 years of age against each of the serogroups A, C, W and Y, at one month after the (study) vaccination with MenACWY.
    End point values
    MenB+MenACWY Group MenACWY Group
    Number of subjects analysed
    295
    303
    Units: Percentage of participants
    number (confidence interval 95%)
        Men A, Baseline (Day 1)
    28.1 (22.8 to 33.9)
    30.0 (24.7 to 35.9)
        Men A, Day 31
    99.7 (98.1 to 100)
    99.3 (97.5 to 99.9)
        Men C, Baseline (Day 1)
    46.3 (40.5 to 52.1)
    44.4 (38.7 to 50.3)
        Men C, Day 31
    99.0 (97.1 to 99.8)
    98.7 (96.6 to 99.6)
        Men W, Baseline (Day 1)
    27.4 (22.4 to 32.9)
    28.4 (23.3 to 34.0)
        Men W, Day 31
    100 (98.8 to 100)
    100 (98.8 to 100)
        Men Y, Baseline (Day 1)
    23.4 (18.6 to 28.7)
    23.0 (18.3 to 28.2)
        Men Y, Day 31
    99.7 (98.1 to 100)
    99.7 (98.2 to 100)
    No statistical analyses for this end point

    Secondary: GMRs against each of the N. meningitidis serogroup Men A, Men C, Men W and Men Y in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination

    Close Top of page
    End point title
    GMRs against each of the N. meningitidis serogroup Men A, Men C, Men W and Men Y in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination [52]
    End point description
    Immune response to MenACWY given with or without rMenB+OMV NZ was measured by bactericidal activity against the four serogroups Men A, Men C, Men W and Men Y in terms of GMRs at one month after MenACWY vaccination compared to the baseline at Day 1/Month 0. GMR was measured within-group. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At 1 month after MenACWY vaccination (i.e.at Day 31) compared to the baseline (Day 1)
    Notes
    [52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assesses the immune response to MenACWY in healthy subjects 16-18 years of age against each of the serogroups A, C, W and Y, at one month after the (study) vaccination with MenACWY.
    End point values
    MenB+MenACWY Group MenACWY Group
    Number of subjects analysed
    295
    303
    Units: Ratio
    geometric mean (confidence interval 95%)
        Men A
    150.2 (120.1 to 187.8)
    145.0 (115.4 to 182.2)
        Men C
    130.0 (97.7 to 173.1)
    131.9 (98.8 to 176.1)
        Men W
    294.2 (229.0 to 378.1)
    279.3 (216.6 to 360.1)
        Men Y
    324.3 (252.2 to 417.0)
    300.0 (232.9 to 386.4)
    No statistical analyses for this end point

    Secondary: Percentage of participants with 4-fold increase in hSBA titers against each of the N. meningitidis serogroup Men A, Men C, Men W and Men Y relative to baseline in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination

    Close Top of page
    End point title
    Percentage of participants with 4-fold increase in hSBA titers against each of the N. meningitidis serogroup Men A, Men C, Men W and Men Y relative to baseline in both MenB+MenACWY and MenACWY Groups after MenACWY vaccination [53]
    End point description
    The immune response to MenACWY vaccine is evaluated by measuring percentage of participants with 4-fold increase for the four serogroups Men A, Men C, Men W and Men Y. The Four-fold increase defined as: - For a pre-vaccination titer <LOD, a post-vaccination titer of >= 4-fold the LOD or >= LLOQ, whichever is greater, - For a pre-vaccination titer >=LOD but <LLOQ, a post vaccination titer of at least 4-fold the LLOQ, - For a pre-vaccination titer >= LLOQ, a post vaccination titer of at least 4-fold the pre-vaccination titer. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At 1 month after MenACWY vaccination (i.e at Day 31) relative to baseline (i.e. Day 1)
    Notes
    [53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assesses the immune response to MenACWY in healthy subjects 16-18 years of age against each of the serogroups A, C, W and Y, at one month after the (study) vaccination with MenACWY.
    End point values
    MenB+MenACWY Group MenACWY Group
    Number of subjects analysed
    293
    296
    Units: Percentage of participants
    number (confidence interval 95%)
        Men A
    98.5 (96.1 to 99.6)
    98.1 (95.6 to 99.4)
        Men C
    95.2 (92.1 to 97.4)
    95.6 (92.6 to 97.6)
        Men W
    98.6 (96.5 to 99.6)
    97.9 (95.6 to 99.2)
        Men Y
    98.6 (96.5 to 99.6)
    98.3 (96.1 to 99.4)
    No statistical analyses for this end point

    Secondary: Percentage of participants with 4-fold increase in hSBA titers relative to baseline in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination

    Close Top of page
    End point title
    Percentage of participants with 4-fold increase in hSBA titers relative to baseline in both MenB+MenACWY and MenB Groups after the second rMenB+OMV NZ vaccination [54]
    End point description
    The immune response to rMenB+OMV NZ vaccine is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains (M14459 [fHbp], 96217 [NadA], NZ98/254 [PorA] and M13520 [NHBA]) in terms of the Four-fold increase defined as: - For a pre-vaccination titer <LOD, a post-vaccination titer of >= 4-fold the LOD or >= LLOQ, whichever is greater, - For a pre-vaccination titer >=LOD but <LLOQ, a post vaccination titer of at least 4-fold the LLOQ, - For a pre-vaccination titer >=LLOQ, a post vaccination titer of at least 4-fold the pre-vaccination titer. Analysis was performed on PPS population. Only those participants with data available at specified timepoint were included in analysis.
    End point type
    Secondary
    End point timeframe
    At 1 month after the second rMenB+OMV vaccination (i.e at Day 91) relative to baseline (i.e. Day 1)
    Notes
    [54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As specified in the Protocol, the analysis assess the imqmune response to rMenB+OMV NZ in healthy subjects 16-18 years of age against N. meningitidis serogroup B test strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA) and M07-0241084 (NHBA), at one month after the second vaccination with rMenB+OMV NZ.
    End point values
    MenB+MenACWY Group MenB Group
    Number of subjects analysed
    273
    266
    Units: Percentage of participants
    number (confidence interval 95%)
        fHbp (M14459)
    57.1 (51.0 to 63.1)
    64.6 (58.5 to 70.4)
        NadA (96217)
    96.0 (92.9 to 98.0)
    98.9 (96.7 to 99.8)
        PorA (NZ98/254)
    51.5 (45.4 to 57.5)
    56.6 (50.4 to 62.7)
        NHBA (M13520)
    55.1 (49.0 to 61.2)
    53.0 (46.8 to 59.1)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited AEs: within 7 days post-vaccination. Unsolicited AEs: within 30 days post-vaccination. All-cause mortality,SAEs,MAAEs, AEs leading to withdrawal, and AESIs: monitored from Day 1 to study end at Day 271 or Day 451, depending on participation date
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    MenB+MenACWY Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of MenACWY vaccine, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of placebo at Day 91.

    Reporting group title
    MenACWY Group
    Reporting group description
    Participants received 1 dose of MenACWY vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day1, 1 dose of rMenB+OMV NZ vaccine each administered at Day 61 and at Day 91.

    Reporting group title
    MenB Group
    Reporting group description
    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of MenACWY at Day 91.

    Serious adverse events
    MenB+MenACWY Group MenACWY Group MenB Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 310 (0.65%)
    7 / 320 (2.19%)
    4 / 308 (1.30%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Lumbar vertebral fracture
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Fibula fracture
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    Abortion spontaneous
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Adjustment disorder with depressed mood
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Drug abuse
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Major depression
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypoglycaemia
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    MenB+MenACWY Group MenACWY Group MenB Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    293 / 310 (94.52%)
    289 / 320 (90.31%)
    293 / 308 (95.13%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Melanocytic naevus
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Vascular disorders
    Pallor
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    General disorders and administration site conditions
    Feeling of body temperature change
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Fatigue
         subjects affected / exposed
    152 / 310 (49.03%)
    159 / 320 (49.69%)
    160 / 308 (51.95%)
         occurrences all number
    265
    303
    306
    Chills
         subjects affected / exposed
    2 / 310 (0.65%)
    3 / 320 (0.94%)
    2 / 308 (0.65%)
         occurrences all number
    2
    3
    3
    Chest pain
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Chest discomfort
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Administration site swelling
         subjects affected / exposed
    31 / 310 (10.00%)
    26 / 320 (8.13%)
    32 / 308 (10.39%)
         occurrences all number
    38
    33
    44
    Administration site pain
         subjects affected / exposed
    281 / 310 (90.65%)
    268 / 320 (83.75%)
    282 / 308 (91.56%)
         occurrences all number
    589
    629
    597
    Administration site induration
         subjects affected / exposed
    31 / 310 (10.00%)
    25 / 320 (7.81%)
    35 / 308 (11.36%)
         occurrences all number
    46
    33
    56
    Administration site erythema
         subjects affected / exposed
    28 / 310 (9.03%)
    28 / 320 (8.75%)
    31 / 308 (10.06%)
         occurrences all number
    39
    30
    37
    Swelling
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Peripheral swelling
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Pain
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Malaise
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    2
    0
    0
    Injection site swelling
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Injection site reaction
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    1
    1
    0
    Injection site pruritus
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Injection site pain
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Injection site hypoaesthesia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Injection site bruising
         subjects affected / exposed
    3 / 310 (0.97%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    3
    0
    2
    Influenza like illness
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences all number
    1
    0
    2
    Induration
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Vaccination site bruising
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Vaccination site erythema
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Vaccination site rash
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Vaccination site swelling
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Pyrexia
         subjects affected / exposed
    14 / 310 (4.52%)
    19 / 320 (5.94%)
    23 / 308 (7.47%)
         occurrences all number
    17
    21
    26
    Immune system disorders
    Multiple allergies
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    5 / 310 (1.61%)
    5 / 320 (1.56%)
    2 / 308 (0.65%)
         occurrences all number
    7
    5
    2
    Abnormal uterine bleeding
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences all number
    2
    0
    2
    Varicocele
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Vaginal discharge
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Pelvic pain
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Heavy menstrual bleeding
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Gynaecomastia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    1
    1
    1
    Cough
         subjects affected / exposed
    1 / 310 (0.32%)
    8 / 320 (2.50%)
    3 / 308 (0.97%)
         occurrences all number
    1
    8
    3
    Upper respiratory tract congestion
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Throat irritation
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Sneezing
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Sinus congestion
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    2
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    1 / 310 (0.32%)
    3 / 320 (0.94%)
    1 / 308 (0.32%)
         occurrences all number
    1
    3
    1
    Rhinitis allergic
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Respiratory symptom
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Respiratory disorder
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    13 / 310 (4.19%)
    10 / 320 (3.13%)
    11 / 308 (3.57%)
         occurrences all number
    13
    10
    11
    Nasal congestion
         subjects affected / exposed
    7 / 310 (2.26%)
    5 / 320 (1.56%)
    3 / 308 (0.97%)
         occurrences all number
    7
    5
    3
    Epistaxis
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Dyspnoea
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    1
    1
    1
    Dysphonia
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Wheezing
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Depression
         subjects affected / exposed
    2 / 310 (0.65%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    2
    1
    2
    Generalised anxiety disorder
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Intentional self-injury
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Investigations
    Arthroscopy
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Blood cholesterol increased
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Injury, poisoning and procedural complications
    Breast procedural complication
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Abdominal injury
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Joint injury
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Head injury
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Foot fracture
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Fibula fracture
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Face injury
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Eye injury
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Distal clavicular osteolysis
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Contusion
         subjects affected / exposed
    0 / 310 (0.00%)
    3 / 320 (0.94%)
    1 / 308 (0.32%)
         occurrences all number
    0
    3
    1
    Concussion
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    3 / 308 (0.97%)
         occurrences all number
    2
    0
    3
    Ligament injury
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Seroma
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Scar
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Procedural pain
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    1
    1
    2
    Open globe injury
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Muscle strain
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    1
    1
    1
    Lip injury
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Limb injury
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    4 / 308 (1.30%)
         occurrences all number
    0
    0
    5
    Ligament sprain
         subjects affected / exposed
    0 / 310 (0.00%)
    3 / 320 (0.94%)
    1 / 308 (0.32%)
         occurrences all number
    0
    3
    1
    Ligament rupture
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Skin laceration
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Thermal burn
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Torus fracture
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Vulvovaginal injury
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Suture related complication
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Congenital, familial and genetic disorders
    Os trigonum
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    1 / 310 (0.32%)
    2 / 320 (0.63%)
    3 / 308 (0.97%)
         occurrences all number
    1
    2
    3
    Headache
         subjects affected / exposed
    178 / 310 (57.42%)
    185 / 320 (57.81%)
    185 / 308 (60.06%)
         occurrences all number
    320
    345
    317
    Migraine
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Paraesthesia
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Sciatica
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Sinus headache
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    2 / 310 (0.65%)
    2 / 320 (0.63%)
    0 / 308 (0.00%)
         occurrences all number
    2
    2
    0
    Neutropenia
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    0 / 310 (0.00%)
    3 / 320 (0.94%)
    0 / 308 (0.00%)
         occurrences all number
    0
    3
    0
    Cerumen impaction
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Tympanic membrane perforation
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Eustachian tube dysfunction
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    1
    1
    0
    Eye disorders
    Photophobia
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Ocular hyperaemia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Myopia
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Episcleritis
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Lacrimation increased
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Astigmatism
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Blepharitis
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Gastrointestinal disorders
    Colitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Cheilitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Aphthous ulcer
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 310 (0.00%)
    5 / 320 (1.56%)
    4 / 308 (1.30%)
         occurrences all number
    0
    5
    5
    Abdominal pain
         subjects affected / exposed
    2 / 310 (0.65%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    2
    1
    1
    Abdominal discomfort
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences all number
    1
    0
    2
    Vomiting
         subjects affected / exposed
    4 / 310 (1.29%)
    6 / 320 (1.88%)
    3 / 308 (0.97%)
         occurrences all number
    4
    6
    3
    Salivary gland mucocoele
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Tooth impacted
         subjects affected / exposed
    1 / 310 (0.32%)
    2 / 320 (0.63%)
    0 / 308 (0.00%)
         occurrences all number
    1
    2
    0
    Toothache
         subjects affected / exposed
    5 / 310 (1.61%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    5
    1
    0
    Nausea
         subjects affected / exposed
    74 / 310 (23.87%)
    94 / 320 (29.38%)
    90 / 308 (29.22%)
         occurrences all number
    105
    132
    119
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Dyspepsia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Diarrhoea
         subjects affected / exposed
    1 / 310 (0.32%)
    4 / 320 (1.25%)
    2 / 308 (0.65%)
         occurrences all number
    1
    6
    2
    Constipation
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Skin and subcutaneous tissue disorders
    Urticaria
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Sensitive skin
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Rash pruritic
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Rash
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    4 / 308 (1.30%)
         occurrences all number
    0
    0
    4
    Pruritus
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    0
    1
    2
    Pityriasis rosea
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Dermatitis contact
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Dermatitis atopic
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Cold sweat
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Alopecia
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Acne
         subjects affected / exposed
    1 / 310 (0.32%)
    2 / 320 (0.63%)
    1 / 308 (0.32%)
         occurrences all number
    1
    2
    1
    Hirsutism
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    0 / 310 (0.00%)
    3 / 320 (0.94%)
    0 / 308 (0.00%)
         occurrences all number
    0
    3
    0
    Micturition urgency
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Endocrine disorders
    Polycystic ovarian syndrome
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    1 / 310 (0.32%)
    2 / 320 (0.63%)
    3 / 308 (0.97%)
         occurrences all number
    1
    2
    3
    Neck pain
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Myalgia
         subjects affected / exposed
    73 / 310 (23.55%)
    88 / 320 (27.50%)
    81 / 308 (26.30%)
         occurrences all number
    86
    116
    112
    Musculoskeletal pain
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Medial tibial stress syndrome
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Joint swelling
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Joint range of motion decreased
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Bone swelling
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Back pain
         subjects affected / exposed
    2 / 310 (0.65%)
    2 / 320 (0.63%)
    0 / 308 (0.00%)
         occurrences all number
    2
    2
    0
    Arthralgia
         subjects affected / exposed
    53 / 310 (17.10%)
    58 / 320 (18.13%)
    46 / 308 (14.94%)
         occurrences all number
    65
    77
    66
    Tendon pain
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Synovial cyst
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Rotator cuff syndrome
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Pain in jaw
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Tendonitis
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Infections and infestations
    Acute sinusitis
         subjects affected / exposed
    0 / 310 (0.00%)
    3 / 320 (0.94%)
    3 / 308 (0.97%)
         occurrences all number
    0
    3
    3
    Bacterial vaginosis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Bacterial vulvovaginitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Beta haemolytic streptococcal infection
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Bronchitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Bronchitis viral
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    COVID-19
         subjects affected / exposed
    9 / 310 (2.90%)
    9 / 320 (2.81%)
    5 / 308 (1.62%)
         occurrences all number
    9
    9
    5
    Chlamydial infection
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    1
    0
    1
    Conjunctivitis
         subjects affected / exposed
    3 / 310 (0.97%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    3
    0
    0
    Conjunctivitis bacterial
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Eye infection
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    0
    1
    0
    Fungal infection
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences all number
    0
    0
    2
    Gastroenteritis
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    1
    1
    2
    Gastroenteritis viral
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    1
    1
    0
    Gonorrhoea
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Hordeolum
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Impetigo
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Influenza
         subjects affected / exposed
    4 / 310 (1.29%)
    2 / 320 (0.63%)
    10 / 308 (3.25%)
         occurrences all number
    4
    2
    10
    Nasopharyngitis
         subjects affected / exposed
    11 / 310 (3.55%)
    18 / 320 (5.63%)
    4 / 308 (1.30%)
         occurrences all number
    11
    18
    5
    Otitis externa
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    2
    0
    0
    Otitis media acute
         subjects affected / exposed
    3 / 310 (0.97%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    3
    1
    3
    Sinusitis bacterial
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Rhinitis
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    1
    1
    3
    Respiratory tract infection viral
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    0 / 308 (0.00%)
         occurrences all number
    1
    1
    0
    Pyuria
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Pilonidal disease
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Pharyngotonsillitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Pharyngitis streptococcal
         subjects affected / exposed
    1 / 310 (0.32%)
    2 / 320 (0.63%)
    3 / 308 (0.97%)
         occurrences all number
    1
    2
    3
    Pharyngitis
         subjects affected / exposed
    2 / 310 (0.65%)
    4 / 320 (1.25%)
    3 / 308 (0.97%)
         occurrences all number
    2
    4
    3
    Staphylococcal infection
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Stitch abscess
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    4 / 310 (1.29%)
    10 / 320 (3.13%)
    1 / 308 (0.32%)
         occurrences all number
    5
    10
    1
    Urethritis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Urinary tract infection
         subjects affected / exposed
    0 / 310 (0.00%)
    2 / 320 (0.63%)
    1 / 308 (0.32%)
         occurrences all number
    0
    2
    1
    Viral infection
         subjects affected / exposed
    3 / 310 (0.97%)
    0 / 320 (0.00%)
    3 / 308 (0.97%)
         occurrences all number
    3
    0
    3
    Viral pharyngitis
         subjects affected / exposed
    0 / 310 (0.00%)
    0 / 320 (0.00%)
    1 / 308 (0.32%)
         occurrences all number
    0
    0
    1
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 310 (0.32%)
    1 / 320 (0.31%)
    2 / 308 (0.65%)
         occurrences all number
    1
    1
    2
    Sinusitis
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    2 / 308 (0.65%)
         occurrences all number
    1
    0
    2
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 310 (0.00%)
    1 / 320 (0.31%)
    1 / 308 (0.32%)
         occurrences all number
    0
    1
    1
    Dehydration
         subjects affected / exposed
    1 / 310 (0.32%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    1
    0
    0
    Vitamin D deficiency
         subjects affected / exposed
    2 / 310 (0.65%)
    0 / 320 (0.00%)
    0 / 308 (0.00%)
         occurrences all number
    2
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    14 Aug 2019
    As per the recommendation from CBER the study has been amended to include an update in development and validation of a new “agar-overlay” serum bactericidal assay using human serum complement (hSBA). Additional changes include validation of the MenB manual to measure immunogenicity of the meningococcal group B vaccine, a modification in the definition of 4-fold increase in post-vaccination hSBA titer definition when the pre-vaccination titer is below the limit of detection, and a modification in the population set to be used for safety analysis wherein the exposed set is to be used for all safety analyses.
    23 Jan 2020
    The inclusion of a booster recommendation in Menveo’s US Prescription Insert, with the recommendation to administer the booster at least 4 years after the priming dose, has only been approved by US FDA in December 2019. As a result, the company intends to align the inclusion criterion in the V72_79 study with the recently introduced booster recommendation in the US and amend the protocol accordingly to allow inclusion of subjects who have received a meningococcal ACWY vaccine 4 years or greater in the past.
    21 Jun 2022
    The purpose of the amendment is to update the exclusion criteria of the protocol, align COVID-19 reporting requirements to local guidelines, and to update the definition of End of Study (EoS).
    11 Oct 2022
    The purpose of the amendment is to shorten the safety follow-up period to 6 months in subjects who have not reached the 6-month safety follow-up after the last dose and to extend the visit window to 28 days post reference day to mitigate the impact of COVID pandemic, including quarantine, mandatory vaccination, or other disturbances in the study procedures.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 19:46:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA